Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | DNLI |
---|---|---|
09:32 ET | 19649 | 23.78 |
09:34 ET | 912 | 23.54 |
09:36 ET | 7288 | 23.77 |
09:38 ET | 2437 | 23.64 |
09:39 ET | 1500 | 23.86 |
09:41 ET | 1525 | 23.69 |
09:43 ET | 2604 | 23.89 |
09:45 ET | 3053 | 23.83 |
09:48 ET | 1850 | 23.94 |
09:50 ET | 1657 | 23.84 |
09:52 ET | 227 | 23.85 |
09:54 ET | 10044 | 23.85 |
09:56 ET | 11079 | 23.955 |
09:57 ET | 4565 | 23.915 |
09:59 ET | 10168 | 23.895 |
10:01 ET | 4455 | 23.95 |
10:03 ET | 19129 | 24.04 |
10:06 ET | 13445 | 23.89 |
10:08 ET | 10975 | 23.84 |
10:10 ET | 8816 | 23.64 |
10:12 ET | 2121 | 23.67 |
10:14 ET | 5027 | 23.63 |
10:15 ET | 4813 | 23.69 |
10:17 ET | 3627 | 23.695 |
10:19 ET | 1427 | 23.67 |
10:21 ET | 3079 | 23.755 |
10:24 ET | 2900 | 23.67 |
10:26 ET | 3579 | 23.6 |
10:28 ET | 2515 | 23.64 |
10:30 ET | 1500 | 23.6 |
10:32 ET | 1019 | 23.615 |
10:33 ET | 2107 | 23.615 |
10:35 ET | 100 | 23.61 |
10:37 ET | 600 | 23.65 |
10:39 ET | 3938 | 23.62 |
10:42 ET | 1400 | 23.55 |
10:44 ET | 1000 | 23.545 |
10:46 ET | 1037 | 23.55 |
10:48 ET | 1800 | 23.5325 |
10:50 ET | 1400 | 23.52 |
10:51 ET | 900 | 23.55 |
10:53 ET | 5763 | 23.55 |
10:55 ET | 1589 | 23.57 |
10:57 ET | 650 | 23.61 |
11:00 ET | 1800 | 23.55 |
11:02 ET | 2145 | 23.63 |
11:04 ET | 1444 | 23.685 |
11:06 ET | 1600 | 23.705 |
11:08 ET | 6718 | 23.735 |
11:09 ET | 13158 | 23.71 |
11:11 ET | 1379 | 23.75 |
11:13 ET | 533 | 23.7 |
11:15 ET | 2051 | 23.6386 |
11:18 ET | 700 | 23.56 |
11:20 ET | 1400 | 23.56 |
11:22 ET | 2257 | 23.54 |
11:24 ET | 1700 | 23.495 |
11:26 ET | 1500 | 23.56 |
11:27 ET | 300 | 23.61 |
11:29 ET | 600 | 23.62 |
11:31 ET | 1310 | 23.52 |
11:33 ET | 100 | 23.515 |
11:36 ET | 500 | 23.52 |
11:38 ET | 1614 | 23.53 |
11:40 ET | 2454 | 23.52 |
11:42 ET | 700 | 23.5 |
11:44 ET | 1000 | 23.58 |
11:45 ET | 1700 | 23.51 |
11:47 ET | 200 | 23.5 |
11:49 ET | 1527 | 23.59 |
11:51 ET | 400 | 23.6 |
11:54 ET | 1136 | 23.56 |
11:56 ET | 400 | 23.54 |
11:58 ET | 721 | 23.5 |
12:00 ET | 627 | 23.53 |
12:02 ET | 1027 | 23.6 |
12:03 ET | 1100 | 23.54 |
12:05 ET | 1512 | 23.54 |
12:07 ET | 1347 | 23.51 |
12:09 ET | 1361 | 23.5 |
12:12 ET | 800 | 23.54 |
12:14 ET | 1200 | 23.55 |
12:16 ET | 2765 | 23.5 |
12:18 ET | 2561 | 23.49 |
12:20 ET | 3434 | 23.5 |
12:21 ET | 1691 | 23.53 |
12:23 ET | 1300 | 23.56 |
12:25 ET | 600 | 23.53 |
12:27 ET | 800 | 23.56 |
12:30 ET | 1100 | 23.5 |
12:32 ET | 700 | 23.53 |
12:34 ET | 1240 | 23.54 |
12:36 ET | 100 | 23.55 |
12:38 ET | 2429 | 23.57 |
12:39 ET | 4020 | 23.53 |
12:41 ET | 1187 | 23.52 |
12:43 ET | 402 | 23.525 |
12:45 ET | 800 | 23.5 |
12:48 ET | 5432 | 23.51 |
12:50 ET | 2893 | 23.5341 |
12:52 ET | 300 | 23.52 |
12:54 ET | 1700 | 23.5 |
12:56 ET | 400 | 23.49 |
12:57 ET | 1600 | 23.52 |
12:59 ET | 400 | 23.51 |
01:01 ET | 3187 | 23.47 |
01:03 ET | 637 | 23.44 |
01:06 ET | 1300 | 23.4 |
01:08 ET | 700 | 23.41 |
01:10 ET | 28466 | 23.49 |
01:12 ET | 17634 | 23.49 |
01:14 ET | 1896 | 23.45 |
01:15 ET | 3628 | 23.525 |
01:17 ET | 894 | 23.53 |
01:19 ET | 1003 | 23.56 |
01:21 ET | 1000 | 23.595 |
01:24 ET | 2056 | 23.56 |
01:26 ET | 291 | 23.5 |
01:28 ET | 200 | 23.54 |
01:30 ET | 1600 | 23.53 |
01:32 ET | 143 | 23.54 |
01:33 ET | 1561 | 23.54 |
01:35 ET | 3957 | 23.62 |
01:37 ET | 200 | 23.605 |
01:39 ET | 500 | 23.69 |
01:42 ET | 500 | 23.64 |
01:44 ET | 1229 | 23.775 |
01:46 ET | 1912 | 23.745 |
01:48 ET | 900 | 23.74 |
01:50 ET | 921 | 23.75 |
01:51 ET | 1911 | 23.75 |
01:53 ET | 400 | 23.73 |
01:55 ET | 2893 | 23.75 |
01:57 ET | 2035 | 23.68 |
02:00 ET | 4369 | 23.71 |
02:02 ET | 500 | 23.73 |
02:04 ET | 1400 | 23.72 |
02:06 ET | 400 | 23.74 |
02:08 ET | 100 | 23.76 |
02:09 ET | 2400 | 23.72 |
02:11 ET | 600 | 23.72 |
02:13 ET | 200 | 23.72 |
02:15 ET | 300 | 23.7 |
02:18 ET | 3240 | 23.77 |
02:20 ET | 100 | 23.78 |
02:22 ET | 1600 | 23.75 |
02:24 ET | 4025 | 23.75 |
02:26 ET | 200 | 23.755 |
02:27 ET | 2319 | 23.78 |
02:29 ET | 1438 | 23.775 |
02:31 ET | 2393 | 23.8 |
02:33 ET | 1450 | 23.835 |
02:36 ET | 1531 | 23.86 |
02:38 ET | 1401 | 23.9567 |
02:40 ET | 7132 | 24 |
02:42 ET | 1678 | 23.98 |
02:44 ET | 200 | 24 |
02:45 ET | 5747 | 23.98 |
02:47 ET | 2038 | 23.92 |
02:49 ET | 3108 | 24 |
02:51 ET | 1147 | 24 |
02:54 ET | 2761 | 24.02 |
02:56 ET | 3842 | 24.005 |
02:58 ET | 1230 | 24 |
03:00 ET | 1906 | 24.02 |
03:02 ET | 3892 | 24.01 |
03:03 ET | 2065 | 23.965 |
03:05 ET | 60397 | 23.94 |
03:07 ET | 2317 | 23.93 |
03:09 ET | 460 | 23.945 |
03:12 ET | 1405 | 23.965 |
03:14 ET | 5000 | 24 |
03:16 ET | 1609 | 24.01 |
03:18 ET | 2900 | 23.975 |
03:20 ET | 1200 | 23.98 |
03:21 ET | 2605 | 23.935 |
03:23 ET | 1270 | 23.985 |
03:25 ET | 17858 | 23.97 |
03:27 ET | 2606 | 24 |
03:30 ET | 1535 | 24 |
03:32 ET | 7234 | 23.96 |
03:34 ET | 1100 | 23.99 |
03:36 ET | 1200 | 24 |
03:38 ET | 2000 | 23.975 |
03:39 ET | 1900 | 23.96 |
03:41 ET | 3009 | 23.9 |
03:43 ET | 1450 | 23.91 |
03:45 ET | 4014 | 23.815 |
03:48 ET | 3368 | 23.78 |
03:50 ET | 3331 | 23.78 |
03:52 ET | 5459 | 23.88 |
03:54 ET | 6294 | 23.89 |
03:56 ET | 7474 | 23.9 |
03:57 ET | 12567 | 23.92 |
03:59 ET | 158826 | 23.94 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Denali Therapeutics Inc | 3.3B | -24.8x | --- |
MorphoSys AG | 2.8B | -5.4x | --- |
Twist Bioscience Corp | 3.3B | -17.5x | --- |
Amicus Therapeutics Inc | 3.1B | -22.0x | --- |
TG Therapeutics Inc | 3.3B | 102.1x | --- |
ADMA Biologics Inc | 3.1B | -673.0x | --- |
Denali Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing a portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases and lysosomal storage disease. The Company has a portfolio of both small molecule and biotherapeutic medicines, comprising seven product candidates in clinical development across seven indications as well as preclinical therapeutic candidates. Its three late-stage development programs include tividenofusp alfa (DNL310) for mucopolysaccharidosis II (MPS II); BIIB122/DNL151 (LRRK2 inhibitor) for Parkinson’s disease; and DNL343 (eIF2B activator) for amyotrophic lateral sclerosis (ALS). SAR443820/DNL788 (RIPK1 inhibitor) is being evaluated in a Phase II study for multiple sclerosis (MS). In addition, it has a Phase I/II study of TAK-594/DNL593 for frontotemporal dementia-granulin (FTD-GRN) and a Phase I/II study of DNL126 for MPS IIIA (Sanfilippo syndrome).
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.3B |
---|---|
Revenue (TTM) | $295.4M |
Shares Outstanding | 142.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.39 |
EPS | $-0.97 |
Book Value | $7.45 |
P/E Ratio | -24.8x |
Price/Sales (TTM) | 11.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -65.54% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.